09.01.2013 - Swiss Debiopharm Group (Lausanne) has licenced Chugai’s preclinical anti-cancer agent FF284.
The Tokyo-based Roche affiliate announced the deal on 8 January 2013, three weeks after the companies signed an agreement giving Debiopharm global rights to develop and commercialise the preclinical compound FF284 (now Debiopharm 1347). Chugai remain the rights to the Japanese market.
Under the same agreement, Chugai will grant a non-exclusive license to develop and commercialise a companion diagnostic for FF284 (Debio 1347). According to the terms of the agreement, Debiopharm and the Roche daughter will conduct a Phase I dose escalation study. In return for the license, Chugai will receive an undisclosed upfront fee, milestone and royalty payments from Debiopharm.
Debio 1347 is an orally available small molecule targeting an undisclosed signalling pathway affecting solid tumour development